Qianyuan Pharmaceutical released its 2026 interim report. Operating revenue was 352 million yuan, down 5.7% year on year. Net profit attributable to the parent was 4.29 million yuan, up 1025.3% year on year. Net profit attributable to the parent after deducting non-recurring items swung to a profit of 5.33 million yuan, compared with a loss of 5.01 million yuan in the same period last year. Net operating cash flow was 81.07 million yuan, up 260.6% year on year. In the second quarter, operating revenue was 178 million yuan, down 6.9% year on year. Net profit attributable to the parent swung to a profit of 940,000 yuan, compared with a loss of 10.01 million yuan in the same period last year. As of the end of the second quarter, total assets were 1.529 billion yuan, down 6.9% from the end of the previous year. Net assets attributable to the parent were 450 million yuan, up 47.6% from the end of the previous year.
Shanxi C&Y Pharmaceutical Group Co LtdNet profit attributable to parent surged 1025.3% year on year, swinging to profit.
